Trials / Completed
CompletedNCT02709798
ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Shenfu Injection on Reperfusion Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Pilot Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Beijing Anzhen Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether perioperative use of Shenfu Injection could reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac magnetic resonance imaging) in patients with STEMI after primary PCI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Shenfu Injection | |
| DRUG | 5% Glucose Injection |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2016-03-16
- Last updated
- 2018-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02709798. Inclusion in this directory is not an endorsement.